BBIO · BridgeBio Pharma Inc
United States · RS rating 64 · As of 2026-11-03
| Price | 74.03 USD |
|---|---|
| 1-day change | -1.3% |
| RS rating (overall / 1M / 3M / 12M) | 64 / 85 / 47 / 66 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 39 / 20 / 40 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -5.3% |
| Sales growth Q/Q | +27.7% |
| Distance from 52-week high | +17.9% |
| Market cap (USD) | $13.9B |